Company / Interest Expense
Abbott Laboratories Interest Expense History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$533.0M
FY2023
5-year range
$533.0M / $670.0M
FY2019-FY2023
Trend
-2.4%
vs FY2022
Sector context
#9 of 43
Health Care
What the data says
Abbott Laboratories's interest expense of $533M is higher than 79% of companies in the Health Care sector (FY2023). Interest Expense has declined for 3 consecutive years, from $826M in FY2020 to $533M in FY2023.
Based on SEC 10-K filings.
$533M in FY2023 with a 5-year CAGR of +4.3%. Top quartile in the Health Care sector.
Improved from $670M to $533M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -13.6%
- 5-Year CAGR
- +4.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 43This company $533.0M Sector average $324.8M
▼
+64.1% above sector average
Key checks
Key Insights
- Abbott Laboratories's interest expense has declined for 3 consecutive years.
- 5-year CAGR of +4.3%, indicating consistent growth.
- In FY2023, interest expense decreased 2.4% year-over-year.
- Ranks #9 out of 43 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 31.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 27.4%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $533.0M | -2.4% |
| FY2022 | $546.0M | -18.5% |
| FY2021 | $670.0M | -18.9% |
| FY2020 | $826.0M | +23.3% |
| FY2019 | $670.0M | +55.5% |
| FY2018 | $431.0M | +164.4% |
| FY2017 | $163.0M | +8.7% |
| FY2016 | $150.0M | +3.4% |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026